Introduction
============

Acute respiratory distress syndrome (ARDS) is a life-threatening condition with non-cardiogenic permeability pulmonary edema characterized by the increased permeability of pulmonary capillary endothelial cells and alveolar epithelial cells, resulting in inflammation, hypoxemia and multiple organ failure ([@b1-etm-0-0-4154],[@b2-etm-0-0-4154]). Mortality rates from ARDS are estimated to be 34--64%; however, with proper treatment, the mortality rate from ARDS may be reduced to \~25% ([@b2-etm-0-0-4154],[@b3-etm-0-0-4154]).

Numerous studies ([@b4-etm-0-0-4154]--[@b7-etm-0-0-4154]) have suggested that an excessive inflammation reaction may be responsible for this apparent mortality. The main causes of inflammation are inflammatory cytokines, including interleukin-1 (IL-1), IL-6, tumor necrosis factor-α (TNF-α), C-reactive protein (CRP) and other factors ([@b7-etm-0-0-4154]). The release of these elevated cytokines contribute to the development of ARDS. Given that ARDS is associated with acute pulmonary inflammation, it is also expected to improve treatment outcomes of anti-inflammation therapies. However, the results of clinical studies using glucocorticoid or corticosteroid to cure ARDS remain controversial.

Although glucocorticoids have a powerful capability in suppressing the inflammatory process ([@b8-etm-0-0-4154],[@b9-etm-0-0-4154]), this effect is correlated with the magnitude and duration of inflammation ([@b7-etm-0-0-4154],[@b10-etm-0-0-4154],[@b11-etm-0-0-4154]). Following the administration of glucocorticoid agents, patients who exhibited a significant reduction in TNF-α and IL-1 usually exhibited an improved outcome ([@b12-etm-0-0-4154],[@b13-etm-0-0-4154]); whereas persistent elevation of inflammatory cytokines predicted a poor outcome in patients with ARDS ([@b11-etm-0-0-4154]). These observations lead researchers to questions when and what doses of glucocorticoid should be used in the treatment of ARDS. Several reviews have investigated these problems ([@b7-etm-0-0-4154],[@b12-etm-0-0-4154],[@b14-etm-0-0-4154],[@b15-etm-0-0-4154]). One review demonstrated that corticosteroids did not significantly reduce hospital mortality when pooling across all trials ([@b12-etm-0-0-4154]); whereas another study reported that it was not clear whether a lower dose of glucocorticoid for persistent ARDS could reduce mortality in the long-term ([@b16-etm-0-0-4154]).

The present study aimed to determine the effects of different doses and application times of glucocorticoid on the mortality of patients with ARDS by conducting a meta-analysis of previous randomized control trials.

Materials and methods
=====================

### Literature search

All studies of interest were identified from electronic databases, including MEDLINE (<https://www.nlm.nih.gov/bsd/pmresources.html>), Embase (<https://www.elsevier.com/solutions/embase-biomedical-research>), Cochrane for English literature (<http://www.cochranelibrary.com/>), and CNKI (<http://www.cnki.net/>) and VIP database for Chinese literature up to November 2013. The following terms were used: Glucocorticoid, corticosteroid, methylprednisolone, hydrocortisone, acute respiratory distress, adult respiratory distress, ARDS, acute respiratory distress syndrome and acute lung injury. In addition to the randomized controlled trials, published reviews and relevant bibliographies from meetings such as the American Thoracic Society, Society of Critical Care Medicine, and the International Society of Intensive Care and Emergency Medicine were also searched and reviewed.

### Inclusion and exclusion criteria

To avoid potential bias, the following inclusion criteria were used: i) Designed as randomized controlled trials; ii) participants aged ≥18 years old with a clear diagnosis of ARDS regardless of etiology, race, nation, and sex; iii) trials should include an intervention arm receiving glucocorticoid treatment and a control arm receiving placebo or standard care. The dose and cycles of the glucocorticoid treatment and data of mortality were presented in published literature or available from authors. The exclusion criteria were as follows: (i) Animal, infant or children study subjects; ii) glucocorticoid therapy used to prevent the occurrence of ARDS but not to treat it; iii) definitive diagnosis standards of ARDS were not presented during the trials; and iv) detailed information about glucocorticoids, including the intervention period, dose and duration of administration were not provided in the literature.

### Data extraction and quality assessment

Population data, number of participants, glucocorticoid administration route, mortality and other endpoints were independently extracted from the studies by two reviewers, and a third reviewer was introduced when disagreements occurred. Important missing data relevant to the study design was also sought, including the blinding method used. Subgroup analyses regarding the dose and duration of glucocorticoid in the treatment of ARDS was also conducted, since the dose and duration of glucocorticoid may be important factors that influence outcomes. The early period of ARDS was defined as the first seven days of the diagnosis of ARDS, and the late period as the seven days following diagnosis of ARDS, as described by Wajanaponsan *et al* ([@b17-etm-0-0-4154]). Low-dose or high-dose therapy was defined according to previous studies ([@b12-etm-0-0-4154],[@b18-etm-0-0-4154],[@b19-etm-0-0-4154]).

Quality assessment of the evidence eligible for the present meta-analysis was performed by reviewers using a scoring method from a previous study ([@b20-etm-0-0-4154]). Differences in scoring were resolved by consensus and the extracted data were recorded carefully and independently verified by two investigators prior to the meta-analysis.

### Data analysis

Relevant data extracted and confirmed by two authors were used for the meta-analysis. All data were typed using Review Manager 5.2 software provided by the Cochrane Collaboration Group (Herlev, Denmark). For dichotomous data, the Mantel-Haenszel method was used to estimate the risk ratio (RR) with a 95% confidence interval (CI). The inverse variance method was applied to analyze continuous data and the mean differences had 95% CIs.

### Statistical analysis

In order to reduce the heterogeneity of the included studies, the heterogeneity of the clinic and methodology were assessed preferentially. In order to test statistical heterogeneity, the χ^2^ test was introduced. P\<0.01 was used to indicate a statistically significant difference. The I^2^ test was used to evaluate the pooled variation between all of the eligible trials. A random-effects model or a fixed-effects model was used to perform meta-analysis, and were selected according to the significance of the heterogeneity, as described previously ([@b21-etm-0-0-4154]). In addition, bias risk was also assessed based on the standards reported in the Cochrane Handbook ([@b21-etm-0-0-4154]). Statistical tests were performed using Stata software, version 12.0 (StataCorp LLC, College Station, TX, USA).

Results
=======

### Study flow

By limiting the search to human clinical studies and excluding animal studies and basic research, 227 articles were determined to be relevant to the topic of acute respiratory distress syndrome and glucocorticoids, and 190 citations were excluded after reviewing the titles and abstracts. The remaining 37 articles were reviewed in full and 14 articles ([@b22-etm-0-0-4154]--[@b34-etm-0-0-4154]) were included for further review. In these 14 studies, two trials ([@b31-etm-0-0-4154],[@b33-etm-0-0-4154]) did not provide mortality data in the text and, although the authors were contacted by e-mail, this data remained unavailable. A total of 14 articles were eligible for the final meta-analysis. A flowchart of the present meta-analysis is presented in [Fig. 1](#f1-etm-0-0-4154){ref-type="fig"}.

### Characteristics and quality of the studies included

According to the inclusion and exclusion criteria, there were 14 articles ([@b18-etm-0-0-4154],[@b22-etm-0-0-4154]--[@b34-etm-0-0-4154]), included in the final analysis, two of which were Chinese ([@b30-etm-0-0-4154],[@b34-etm-0-0-4154]). The basic characteristics and quality of the studies included are presented in [Tables I](#tI-etm-0-0-4154){ref-type="table"} and [II](#tII-etm-0-0-4154){ref-type="table"}. A total of 1,441 patients with ARDS were included, with 774 cases in the treatment group and the remaining 667 in the control. Standard care, mechanical ventilation, and other supportive care was applied to patients in both groups. Nine studies ([@b24-etm-0-0-4154]--[@b30-etm-0-0-4154],[@b34-etm-0-0-4154]) used low-dose therapy and high-dose therapy was studied in three trials ([@b22-etm-0-0-4154],[@b23-etm-0-0-4154],[@b32-etm-0-0-4154]). There were 11 studies ([@b18-etm-0-0-4154],[@b22-etm-0-0-4154]--[@b26-etm-0-0-4154],[@b29-etm-0-0-4154],[@b30-etm-0-0-4154],[@b32-etm-0-0-4154]--[@b34-etm-0-0-4154]) that defined as glucocorticoid intervention at the early phase of ARDS onset, and two studies ([@b27-etm-0-0-4154],[@b28-etm-0-0-4154]) were considered to treat ARDS with glucocorticoid during the late period. Furthermore, two studies ([@b27-etm-0-0-4154],[@b28-etm-0-0-4154]) provided data for the early and late treatment of ARDS. Illness severity scores were not applied in the present study.

As shown in [Table II](#tII-etm-0-0-4154){ref-type="table"}, the quality of the studies included was acceptable for the comparison of the effect of glucocorticoid therapy on the mortality of ARDS, although some studies ([@b18-etm-0-0-4154],[@b25-etm-0-0-4154],[@b29-etm-0-0-4154]--[@b31-etm-0-0-4154],[@b34-etm-0-0-4154]) failed to provide a clear method of blinding, and a few studies ([@b18-etm-0-0-4154],[@b24-etm-0-0-4154],[@b34-etm-0-0-4154]) revealed limitations in the sample size, anti-inflammatory agents and in the risk of bias of glucocorticoid stopping for perceived improvement.

### Meta-analysis

Initially, a meta-analysis of the mortality, incident infection, days remained alive and off mechanical ventilation, lung injury scores, multiple organ failure and PaO~2~/FiO~2~ ratio was planned. However, due to the limited data available, only a pooled analysis of the mortality, incident infection and days alive and off mechanical ventilation was conducted. Subgroup analysis of the mortality data accordingly to the different doses and duration of glucocorticoid therapy was also included.

### Effect of glucocorticoid on mortality in ARDS patients

A total of 12 trials ([@b18-etm-0-0-4154],[@b22-etm-0-0-4154]--[@b30-etm-0-0-4154],[@b32-etm-0-0-4154],[@b34-etm-0-0-4154]) were selected to assess whether glucocorticoid treatment was beneficial to patients with ARDS by reducing mortality. The main findings are depicted in [Fig. 2](#f2-etm-0-0-4154){ref-type="fig"}, estimating a value of 0.68 for the RR of overall mortality (95% CI, 0.50--0.91). Supported by the pooled analysis, a significant difference was identified in the glucocorticoid intervention group for lowering the overall mortality when compared with the control group (P\<0.05).

As previously described, studies of low-dose and high-dose glucocorticoid treatment with a threshold value of 2 mg/kg/d were identified. As presented in [Fig. 2](#f2-etm-0-0-4154){ref-type="fig"}, there were 9 articles ([@b18-etm-0-0-4154],[@b24-etm-0-0-4154]--[@b30-etm-0-0-4154],[@b34-etm-0-0-4154]) comparing the impact of low-dose treatment of glucocorticoid on mortality rates of ARDS patients with the controls. Significantly reduced mortality was identified in the low-dose intervention group compared with the control, and the combined RR was 0.57 with a 95% CI between 0.39 and 0.84 (P\<0.05), indicating that treating ARDS with low-dose administration of glucocorticoid may sufficiently decrease the mortality of ARDS by a relative ratio of 0.57. However, this result was no longer beneficial when comparing low-dose glucocorticoid with the control in late steroid rescue studies (P\>0.05). Only three articles ([@b22-etm-0-0-4154],[@b23-etm-0-0-4154],[@b32-etm-0-0-4154]) studied the effect of high-dose glucocorticoid on the mortality rates of ARDS, and the pooled data ([Fig. 2](#f2-etm-0-0-4154){ref-type="fig"}) failed to support the hypothesis that high-dose glucocorticoid was able to significantly benefit ARDS patients, though a plausible trend was identified (RR, 0.88; 95% CI, 0.51--1.53, P\>0.05).

Given that the administration time of glucocorticoid was able to influence the outcome, a subgroup analysis of administration of glucocorticoid at early and late periods of ARDS was performed using the data from 13 trials ([@b18-etm-0-0-4154],[@b22-etm-0-0-4154]--[@b30-etm-0-0-4154],[@b32-etm-0-0-4154]--[@b34-etm-0-0-4154]). Data presented in [Fig. 3](#f3-etm-0-0-4154){ref-type="fig"} suggested a significant reduction of mortality in the early treatment group (RR, 0.37; 95% CI, 0.16--0.86, P\<0.05), whereas glucocorticoid therapy during the late period of ARDS was demonstrated to be insufficient to significantly reduce mortality (RR, 0.59; 95% CI, 0.34--1.03, P\>0.05). Furthermore, sensitivity analysis indicated that the low dose of glucocorticoid provided an improved outcome when excluding studies of low quality (RR, 0.40; 95% CI, 0.21--0.74, P=0.004).

Glucocorticoid therapy was also analyzed with regard to the bias of glucocorticoid termination for perceived benefit. A total of 13 trials ([@b18-etm-0-0-4154],[@b22-etm-0-0-4154]--[@b30-etm-0-0-4154],[@b32-etm-0-0-4154]--[@b34-etm-0-0-4154]) were selected in which participants received glucocorticoid administration for 7 days or less and compared with those that received treatment for more than 7 days. The results illustrated that a longer duration of treatment with glucocorticoid provided a better outcome (RR, 0.44; 95% CI, 0.30--0.64, P\<0.05; [Fig. 4](#f4-etm-0-0-4154){ref-type="fig"}), whereas shorter therapy did not exhibit statistical significance (RR, 0.77; 95% CI, 0.52--1.13, P\>0.05; [Fig. 4](#f4-etm-0-0-4154){ref-type="fig"}).

### Effect of glucocorticoid treatment on days remaining alive and off mechanical ventilation in patients with ARDS

Five trials ([@b26-etm-0-0-4154]--[@b28-etm-0-0-4154],[@b30-etm-0-0-4154],[@b33-etm-0-0-4154]) studied whether glucocorticoid therapy was able to increase the number of days remaining alive and off mechanical ventilation in patients with ARDS. Mechanical ventilation-free days were significantly increased in the treatment group when compared with the control (RR, 3.08; 95% CI, 1.49--4.68, P\<0.05; [Fig. 5](#f5-etm-0-0-4154){ref-type="fig"}).

### Effect of glucocorticoid therapy on the PaO~2~/FiO~2~ ratio in patients with ARDS

Only four trials ([@b25-etm-0-0-4154],[@b28-etm-0-0-4154],[@b30-etm-0-0-4154],[@b31-etm-0-0-4154]) provided information on the PaO~2~/FiO~2~ ratio in the glucocorticoid and control groups. It was shown that there was evident heterogeneity between the studies, therefore a random model was selected to perform this analysis. Analysis of the PaO~2~/FiO~2~ ratio in the treatment and control groups did not exhibit a significant difference (RR, 17.75; 95% CI, −65.23--100.73, P\>0.05; [Fig. 6](#f6-etm-0-0-4154){ref-type="fig"}), favoring the application of glucocorticoid in the ARDS treatment.

### Effect of glucocorticoid treatment on incident infections in patients with ARDS

Seven studies ([@b22-etm-0-0-4154],[@b23-etm-0-0-4154],[@b25-etm-0-0-4154]--[@b28-etm-0-0-4154],[@b34-etm-0-0-4154]) compared the influence of glucocorticoids on novel infections in patients with ARDS. As shown in [Fig. 7](#f7-etm-0-0-4154){ref-type="fig"}, the pooled RR was 1.00 (95% CI, 0.44--2.25), indicating that the risk of infection for patients receiving glucocorticoid therapy was not significantly different when compared with the control group (P\>0.05).

### Publication bias

An analysis was also performed in order to evaluate the possible publication bias in the studies included, and the results were negative ([Fig. 8](#f8-etm-0-0-4154){ref-type="fig"}).

Discussion
==========

The present meta-analysis suggested that an evident reduction in the mortality of patients with ARDS was observed following low-dose glucocorticoid treatment during the early stages of ARDS. A favorable outcome was identified in the subgroup analysis of the effect of glucocorticoid on the 28-day mortality in the treatment group. However, a high-dose of glucocorticoid and administration of glucocorticoid during the late period of ARDS did not significantly improve the outcome of patients with ARDS, although trends were identified in favor of the glucocorticoid treatment. The present study identified that the duration of glucocorticoid therapy was a factor affecting the effect of treatment as administration of glucocorticoid for \>7 days significantly reduced the mortality of ARDS patients. The results also suggested that the number of days the patients remained alive and off mechanical ventilation as well as the ratio of PaO~2~/FiO~2~ improved after the administration of glucocorticoid without significantly increasing the incidence of infection after the onset of ARDS.

A number of reviews ([@b7-etm-0-0-4154],[@b12-etm-0-0-4154],[@b16-etm-0-0-4154],[@b20-etm-0-0-4154],[@b35-etm-0-0-4154],[@b36-etm-0-0-4154]) on the effect of therapeutic glucocorticoid in ARDS have been published recently; however, the recommendations from these studies did not reach a consensus. The meta-analysis performed by Peter *et al* ([@b20-etm-0-0-4154]) included five trials that assessed whether steroids were able to significantly improve outcomes. The results demonstrated that steroid therapy was associated with a clear trend towards reduced mortality. Nevertheless, a definitive role of steroid use in treating ARDS was not established. This result may be explained by the design of the analysis as a subgroup analysis of mortality based on the dose and duration of the therapy was not performed and the sample size of the patients was relatively small. In addition, a review by Thompson ([@b16-etm-0-0-4154]) investigated the role of glucocorticoid in early and late ARDS, and indicated that short-duration and high-dose of steroids in patients with or at risk for ARDS revealed a trend for a worse outcome, whereas the impact of a low-dose on the mortality rate in persistent patients with ARDS was unclear. Another review by Thompson ([@b35-etm-0-0-4154]), indicated that a short duration of high-dose glucocorticoid treatment was not effective for early ARDS. These results should be viewed with caution due to the common features of patients, treatment regimens and of the method of measuring the outcomes (28-day mortality for example) of their included studies, which all contributed to an increase in the bias. By contrast, Lamontagne *et al* ([@b12-etm-0-0-4154]) performed a meta-analysis in order to determine the impact of steroids on mortality rates from ARDS, acute lung injury and severe pneumonia, and they concluded that low-dose steroids administrated at the first two weeks of the illness may reduce mortality. Furthermore, a study by Meduri *et al* ([@b36-etm-0-0-4154]) included five trials and concluded that prolonged glucocorticoid therapy significantly improved the outcomes of patients with ARDS, and had a distinct survival benefit in preventing ARDS if initiated properly. Another review by Meduri *et al* ([@b7-etm-0-0-4154]) demonstrated a similar result that glucocorticoid therapy was associated with a significant risk reduction in mortality and improved mechanical ventilation-free days. The findings of the present meta-analysis were in accordance with the study by Lamontagne *et al* ([@b12-etm-0-0-4154]), although heterogeneity of study subjects existed. Low-dose glucocorticoid and early administration was demonstrated to be effective in improving the survival outcome and other factors associated with lung function or treatment efficacy in patients with ARDS. These findings indicated that a proper dose of glucocorticoid at the beginning and even prior to the onset of ARDS may provide a significant improvement not only in preventing the development of ARDS but also in reducing ARDS-associated mortality.

The apparent differential effect of an early and low dose of glucocorticoid therapy in ARDS, which was observed in the present study, has been reported previously ([@b12-etm-0-0-4154]). However, the underlying mechanism for this condition remains unclear. As explained previously, cytokines including TNF-α, IL-1 and IL-6 have been indicated to have a pathophysiological role in the development of ARDS. Early administration of glucocorticoid at a low-dose may suppress the release of these factors and decrease their levels. However, to date the efficacy of low-dose steroids for the remission of inflammation and improvement of survival has not been fully elucidated in ARDS ([@b1-etm-0-0-4154]). The optimal time for administering glucocorticoid remains under investigation. Steroid-associated benefits may start at the first two weeks of ARDS whereas later administration may cause a loss of the benefits of the steroids ([@b37-etm-0-0-4154],[@b38-etm-0-0-4154]). In the studies included in the present meta-analysis, the initial use of glucocorticoid ranged from \<1 day to a few days after ARDS was diagnosed, making the treatment outcome on the basis of different beginning time of treatment.

Glucocorticoid administration was not demonstrated to increase the incidence of infection, however, a trend of an increasing risk of infection was observed. Instead, glucocorticoid administration increased the number of days the patients remained alive and off mechanical ventilation and improved the PaO~2~/FiO~2~ ratio, indicating an economical benefit by decreasing the cost of supportive care as well as an improved lung function of exchanging gas and providing oxygen for the whole body. These observations indicate the efficacy of early administration of low dose glucocorticoids in improving the clinical outcomes without significantly increasing the incidence of infection if they are used in the treatment of ARDS.

Although the present study attempted to avoid possible bias and to reduce heterogeneity by selecting evidence and performing this meta-analysis, there are still a few limitations that remain. Firstly, only a low number of studies were used for the analysis of mortality, incident infection rate and PaO~2~/FiO~2~ ratio. In the subgroup analysis of mortality a further reduced number of patients and data were selected, thus increasing the risk of selective bias. Secondly, apart from the definition of ARDS the agents used for treatment and doses of agents were not consistent with the studies, thus challenging the confirmed efficacy of glucocorticoid determined by the present study. For the facilitation of the meta-analysis, a low or high dose of treatment agent was introduced based on the equality effect of steroids. This may underestimate or overestimate the effect of steroids as it failed to adequately compare their respective effects at exactly the same dose and agent. Thirdly, it remains unclear whether glucocorticoids are safe as some studies that were included presented limited information on the incidence of infections. In summary, more randomized controlled trials with a larger number of events are required in order to confirm the results of the present study. Although there were limitations to the present study, the present study was able to provide reliable and clinically useful results.

In conclusion, early administration of low-dose glucocorticoids during the early period of ARDS onset is recommended based on reduced mortality, improvements in the PaO~2~/FiO~2~ ratio and mechanical ventilation-free days without increasing the risk of incident infection.
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###### 

Characteristics of studies included.

                         Numbers of participants                                                                                                                          
  ---------------------- ------------------------- ------ --------------- ---------------------- -------------------------------------------------------------- --------- ----
  Hwangbo *et al*          23                        8    3/7             Early phase            Methylprednisolone, 8 mg kg^−1^d^−1^ for 7 days, low-dose      Not RCT   18
  Weigelt *et al*          39                        42   18/13           Early phase            Methylprednisolone, 120 mg kg^−1^d^−1^ for 2 days, high-dose   RCT       22
  Bernard *et al*          50                        49   30/31           Early phase            Methylprednisolone, 120 mg kg^−1^d^−1^ for 1 day, high-dose    RCT       23
  Marik *et al*            14                        16   1/3             Early phase            Hydrocortisone, 10 mg/kg, once, low-dose                       RCT       24
  Confalonieri *et al*     23                        23   0/7             Early phase            Hydrocortisone, 240 mg/d for 7 days, low-dose                  RCT       25
  Annane *et al*           85                        92   45/62           Early phase            Hydrocortisone, 200 mg/d for 7 days, low-dose                  RCT       26
  Steinberg, *et al*       89                        91   18/24           Early and late phase   Methylprednisolone, 2 mg kg^−1^d^−1^ for 25 days, low-dose     RCT       27
  Meduri *et al*           63                        28   15/12           Early and late phase   Methylprednisolone, 1 mg kg^−1^d^−1^ for 28 days, low-dose     RCT       28
  Mikami *et al*           15                        16   1/0             Early phase            Prednisolone, 40 mg for 3 days, low-dose                       RCT       29
  Wan *et al*              38                        43   5/3             Early phase            Dexamethasone, 1 mg kg^−1^d^−1^ for 3 days, low-dose           RCT       30
  Ferguson *et al*       135                         88   Not available   Early phase            Corticosteroids, not available                                 RCT       31
  Azevedo *et al*        133                       133    20/40           Early phase            Methylprednisolone, 1 g for 3 days, high-dose                  RCT       32
  Seam *et al*             55                        24   Not reported    Early phase            Methylprednisolone, not available                              RCT       33
  Liu *et al*              12                        14   2/7             Early phase            Hydrocortisone, 300 mg/d for 7 days, low-dose                  RCT       34

ARDS, acute respiratory distress syndrome; RCT, randomized control trials.

###### 

Quality assessment of studies included.

  Study                  Randomization   Allocation   Blinding   No baselines heterogeneity   Clear criteria of inclusion and exclusion   Clear regimen   Clear endpoints   Follow-up   Total score   Refs.
  ---------------------- --------------- ------------ ---------- ---------------------------- ------------------------------------------- --------------- ----------------- ----------- ------------- -------
  Hwangbo *et al*        0               0            0          1                            1                                           1               1                 1           5             18
  Weigelt *et al*        1               0            1          1                            1                                           1               1                 0           6             22
  Bernard *et al*        1               0            1          1                            1                                           1               1                 1           7             23
  Marik *et al*          1               0            1          1                            1                                           1               1                 0           6             24
  Confalonieri *et al*   1               0            0          1                            1                                           1               1                 1           6             25
  Annane *et al*         1               0            1          1                            1                                           1               1                 1           7             26
  Steinberg *et al*      1               0            1          1                            1                                           1               1                 1           7             27
  Meduri *et al*         1               0            1          0                            1                                           1               1                 0           5             28
  Mikami *et al*         1               0            0          1                            1                                           1               1                 0           5             29
  Wan *et al*            1               0            0          1                            1                                           1               1                 1           6             30
  Ferguson *et al*       1               0            0          1                            1                                           1               1                 0           5             31
  Azevedo *et al*        1               0            1          1                            1                                           1               1                 1           7             32
  Seam *et al*           1               0            1          1                            1                                           1               1                 0           6             33
  Liu *et al*            1               0            0          1                            1                                           1               1                 0           5             34

Low quality of evidence scores between 0 to 2; moderate quality scores between 3 to 5; high quality scores between 6 to 8.
